1. Show article details.

    Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update

    GlobeNewswire – 1:45 PM ET 08/06/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will host a conference call to discuss its Q2 2020 financial results and provide a business update at 8:30 a.m. on Friday, August 14, 2020. The company will issue a pre-market earnings announcement the same day.

  2. Show article details.

    BRIEF-Ocugen Says FDA Granted Orphan Drug Designation For Ocu400 Gene Therapy

    Reuters – 9:09 AM ET 07/27/2020

    Ocugen Inc (OCGN): * OCUGEN GRANTED FDA ORPHAN DRUG DESIGNATION FOR OCU400 GENE THERAPY FOR THE TREATMENT OF RHO MUTATION-ASSOCIATED RETINAL DEGENERATIVE DISEASE Source text for Eikon: Further company coverage:

  3. Show article details.

    Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

    GlobeNewswire – 7:30 AM ET 07/27/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced the U.S. Food and Drug Administration granted the third Orphan Drug Designation for OCU400 in the treatment of RHO mutation-associated retinal degeneration.

  4. Show article details.

    Ocugen to Present at World Orphan Drug Congress USA 2020 Conference

    GlobeNewswire – 5:15 PM ET 07/21/2020

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at the World Orphan Drug Congress USA 2020 Conference, to be held virtually from August 24-27, 2020.

  5. Show article details.

    BRIEF-Ocugen Says Chief Medical Officer & Chief Scientific Officer Were Notified Of Their Employment Termination

    Reuters – 8:57 AM ET 06/16/2020

    Ocugen Inc (OCGN): * OCUGEN (OCGN) -CHIEF MEDICAL OFFICER & CHIEF SCIENTIFIC OFFICER WERE NOTIFIED OF THEIR EMPLOYMENT TERMINATION EFFECTIVE JULY 15 & DEC 31,RESPECTIVELY. * OCUGEN (OCGN) - ON JUNE 15, COMMUNICATED TO FIVE EMPLOYEES NOTICE OF TERMINATION OF THEIR EMPLOYMENT Source: Further company coverage:

  6. Show article details.

    BRIEF-Ocugen Says Filed A Prospectus Supplement Related To Offering For Up To $6.2 Mln Of Shares

    Reuters – 6:36 PM ET 06/12/2020

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN) - FILED A PROSPECTUS SUPPLEMENT RELATED TO OFFERING FOR UP TO $6.2 MILLION OF SHARES Source text: Further company coverage:

  7. Show article details.

    BRIEF-Ocugen Inc - Filed A Prospectus Supplement Related To Offering For Up To $6.2 Million Of Shares

    Reuters – 5:04 PM ET 06/12/2020

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN) - FILED A PROSPECTUS SUPPLEMENT RELATED TO OFFERING FOR UP TO $6.2 MILLION OF SHARES Source text for Eikon: https://bit.ly/37mBUIa Further company coverage:

  8. Show article details.

    Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board

    GlobeNewswire – 8:30 AM ET 06/03/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved eye diseases, today announced the appointment of Dr. Mohamed Genead as chair of the Ocugen (OCGN), Inc. Retina Scientific Advisory Board, which is comprised of prominent experts who provide strategic advice, clinical and regulatory support, and scientific...

  9. Show article details.

    BRIEF-Ocugen To Discontinue Phase 3 oGVHD Trial

    Reuters – 9:27 AM ET 06/01/2020

    Ocugen Inc (OCGN): * OCUGEN TO DISCONTINUE PHASE 3 OGVHD TRIAL. * OCUGEN (OCGN) - STUDY WAS NOT STOPPED BASED ON SAFETY CONCERNS. * OCUGEN (OCGN) - DATA MONITORING COMMITTEE INDICATED PHASE 3 OGVHD TRIAL WAS UNLIKELY TO MEET CO-PRIMARY ENDPOINTS UPON COMPLETION. * Ocugen Inc (OCGN) - STOPPING OGVHD TRIAL BASED ON RESULTS OF PRE-PLANNED INTERIM SAMPLE SIZE ANALYSIS CONDUCTED BY AN INDEPENDENT DATA MONITORING COMMITTEE.

  10. Show article details.

    Ocugen to Discontinue Phase 3 oGVHD Trial

    GlobeNewswire – 9:20 AM ET 06/01/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today announced the decision to discontinue the Phase 3 trial of OCU300 for ocular Graft vs. “This is disappointing news, especially for those who suffer from oGVHD.

  11. Show article details.

    Ocugen Provides Business Update and First Quarter 2020 Financial Results

    GlobeNewswire – 7:30 AM ET 05/08/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today reported first quarter 2020 financial results along with a general business update. “We reached a significant milestone in our Phase 3 trial with OCU300 for ocular Graft vs.

  12. Show article details.

    Ocugen Announces Completion of Warrant Exchange

    GlobeNewswire – 9:38 AM ET 04/22/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced the amendment and exchange of the Series A warrants issued pursuant to the Securities Purchase Agreement dated June 13, 2019 with the holders of all outstanding Series A warrants.

  13. Show article details.

    Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors

    GlobeNewswire – 8:01 AM ET 04/07/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced the appointment of Kirsten Castillo and Prabhavathi Fernandes, Ph.D. to its board of directors.

  14. Show article details.

    Ocugen Provides Business Update and Full Year 2019 Financial Results

    GlobeNewswire – 7:30 AM ET 03/27/2020

    Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020 Conference Call and Webcast Today at 8:30 a.m. ET Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today reported full year 2019 financial results along with a general bus...

  15. Show article details.

    Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update

    GlobeNewswire – 7:30 AM ET 03/20/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced that it will release its 2019 financial results and provide a business update before the open of the U.S. financial markets on Friday, March 27, 2020.

  16. Show article details.

    Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

    GlobeNewswire – 7:30 AM ET 03/03/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced today the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases.

  17. Show article details.

    Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference

    GlobeNewswire – 7:30 AM ET 02/10/2020

    Ocugen, Inc. (OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference, to be held February 17-18, 2020 in Hollywood, Florida.

Page:

Today's and Upcoming Events

  • Aug
    14

    OCGN to announce Q2 earnings (Confirmed)

Past Events (last 90 days)

  • May
    08

    OCGN announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.